Investigation on the status of diagnosis and treatment of chemotherapy-induced anemia

LUO Xu; ZHANG Yue; SHU Di-tian; RONG Qi-xiang; TIAN Ying-xia; SHI Yan-xia

doi:10.19538/j.nk2025040109

Abstract：Objective A nationwide survey on the diagnosis,treatment,and management of chemotherapy-induced anemia(CIA)among Chinese oncology clinical doctors has been initiated in order to study the issues in the field of CIA treatment and to gain a thorough understanding of the current state and concept of CIA management among Chinese clinical doctors.Methods The"Chemotherapy-induced Anemia Survey"was an online survey of Gansu Provincial Cancer Hospital that was made available to clinical physicians from various levels of medical institutions nationwide between January and May 2024.CIA's effects on tumor treatment,clinical practice measures and objectives,CIA management of antibody drug conjugates(ADCs),and methods for physicians to access the most recent CIA information were all assessed.Results The median and quartile incidence of CIA in patients prescribed chemotherapy regimens in the past 3 months among the physicians participating in the study was 10(3,30),and anemia-related chemotherapy dose delay/reduction(DDR)occurred in 22％of cases.Only 33％of physicians,according to the survey's results,think that CIA should be treated as soon as possible,meaning that anemia should be treated promptly when hemoglobin(Hb)≤100 g/L.In clinical practice,40％of physicians still start treating CIA when Hb ≤80 g/L.During chemotherapy,71％of physicians thought that the Hb level should be kept between 90-110 g/L.49％of physicians thought that treatment was necessary for ADC-induced anemia when Hb≤80 g/L.Conclusion Inadequate knowledge of the effects and harm of CIA,low treatment targets,and too late treatment initiation are some issues in the field of CIA treatment that may be connected to the limited clinical treatment options for anemia.